AcelRx Chief Commercial Officer David Chung resigns AcelRx Pharmaceuticals announced that David Chung has resigned as Chief Commercial Officer in order to assume the role of CEO of a medical device company. Richard King, the company's President and CEO, will assume the duties and responsibilities of the Chief Commercial Officer, and will lead the continued build-out of the commercial organization and launch preparation for Zalviso until a suitable replacement is found. The Company has begun a search for Mr. Chung's replacement.
AcelRx to present positive efficacy results in Phase 3 trial of Zalviso AcelRx Pharmaceuticals will present safety and efficacy data from a Phase 3 pivotal trial evaluating the Zalviso sufentanil sublingual tablet system for the treatment of moderate-to-severe acute pain following joint replacement surgery at the American Society of Regional Anesthesia and Pain Medicine 13th Annual Pain Medicine Meeting on November 13th to November 16th in San Francisco. Data from the sublingual sufentanil tablet system development program highlights efficacy across various demographic populations